


Data Sheet

Product Name:	Carbacyclin
Cat. No.:	CS-0045198
CAS No.:	69552-46-1
Molecular Formula:	C ₂₁ H ₃₄ O ₄
Molecular Weight:	350.49
Target:	Prostaglandin Receptor
Pathway:	GPCR/G Protein
Solubility:	10 mM in DMSO



BIOLOGICAL ACTIVITY:

Carbacyclin is a PGI₂ analogue, acts as a **prostacyclin (PGI₂) receptor** agonist and vasodilator, and potently inhibits platelet aggregation. IC₅₀ & Target: PGI₂ receptor^[1] **In Vitro:** Carbacyclin is an agonist of prostacyclin (PGI₂) receptor^[1]. Carbacyclin acts as an inhibitor of platelet aggregation induced by ADP or collagen in vitro^[2]. Carbacyclin is a PGI₂ analogue, activates CPT-1 mRNA expression through PPAR δ , independent of the IP receptor signaling pathway. Carbacyclin (0.02 μ M to 20 μ M) activates the IP receptor signaling pathway via PKA, and such an effect is inhibited by H-89, a PKA inhibitor. Carbacyclin (0.02-80 μ M) increases PPARE promoter activity via PPAR δ independent of the IP receptor signaling pathway in cardiomyocytes^[3]. **In Vivo:** Carbacyclin is 0.03 times as active as prostacyclin on inhibiting platelet aggregation in human, dog or rabbit plasma^[2]. Carbacyclin (100 μ g, i.p.) induces CPT-1 mRNA expression in murine heart^[3].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: ^[3]Primary cultures of **neonatal rat cardiomyocytes** are prepared from the ventricles of 1-day-old Wistar rats, and are seeded at a density of 4×10^5 /6-well plastic plates, 9×10^5 /60 mm dishes, or 3×10^6 /100 mm dishes with Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). After 40 h of incubation, cultured cardiomyocytes are serum-starved for 8 h before **Carbacyclin** stimulation.

Animal Administration: ^[3]Mice^[3]

Ten to twelve week-old male **C57BL/6 mice** (20-25 g) are used in the experiment. Mice (n = 4) are injected **intraperitoneally with 100 μ g of Carbacyclin**, and are sacrificed at the times indicated. The hearts are excised, and the ventricles are then homogenized with 3 mL of Isogen for the following total RNA extraction procedure^[3].

References:

- [1]. Takasuka M, et al. FTIR spectral study of intramolecular hydrogen bonding in thromboxane A₂ receptor agonist (U-46619), prostaglandin (PG)E₂, PGD₂, PGF₂ α , prostacyclin receptor agonist (carbacyclin), and their related compounds in dilute CCl₄ solution: structure-activity relationships. J Med Chem. 1994 Jan 7;37(1):47-56.
- [2]. Whittle BJ, et al. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 1980 Apr;19(4):605-27.
- [3]. Kuroda T, et al. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) δ independent of the IP receptor signaling pathway. J Mol Cell Cardiol. 2007 Jul;43(1):54-62.

CAIndexNames:

Pentanoic acid, 5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-1-octenyl]-2(1H)-pentalenylidene]-, (5E)-

SMILES:

O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)CCCC)[C@@]2([H])C\1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA